Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors [0.03%]
瑞戈塞奇布治疗晚期、复发或难治性恶性实体瘤I期研究
Jun Sato,Yuki Katsuya,Takafumi Koyama et al.
Jun Sato et al.
Purpose: Aberrant splicing plays a significant role in cancer progression, yet targeted treatments are lacking. Rogocekib (developmental name CTX-712) is a potent oral inhibitor of CDC2-like kinase (CLK) that targets RNA ...
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer [0.03%]
萨瓦图单抗戈维亭治疗复发性子宫癌的二期疗效和安全性评估
Alessandro D Santin,Dana M Roque,Eric Siegel et al.
Alessandro D Santin et al.
Purpose: Endometrial cancer (EC) patients who progress after chemotherapy/immunotherapy have limited treatment options. We evaluated the activity and safety of sacituzumab govitecan (SG), a Trop-2-directed ADC, in patient...
Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy [0.03%]
线粒体成像检测到癌症免疫治疗后的早期心脏变化
Hee-Don Chae,Uttam Shrestha,Millie Das et al.
Hee-Don Chae et al.
Purpose: Advances in cancer therapy have improved survival but increased the risk of treatment-related cardiotoxicity, which remains difficult to detect early with existing biomarkers. [¹⁸F]F-AraG is a PET tracer that t...
Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig [0.03%]
关于双重检查点抑制剂疗法的再思考——来自Volrustomig的启示
Jong Chul Park,Justin F Gainor
Jong Chul Park
Dual PD-1/CTLA-4 inhibition improves outcomes in several cancers but remains limited by toxicity. A recent article reports the first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody, demonstrating durable responses, bu...
A phase 2 study of the MEK1/2 inhibitor luvometinib in patients with extracranial arteriovenous malformations [0.03%]
一项关于MEK1/2抑制剂luvometinib治疗体外动静脉畸形患者的2期研究
Chen Hua,Zhuli Wu,Xingli Wang et al.
Chen Hua et al.
Purpose: Extracranial arteriovenous malformation (AVM) is a rare and debilitating condition with significant morbidity. Clinical trial evidence for targeted therapies remains limited. We evaluated the efficacy and safety ...
Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy [0.03%]
单细胞转录组揭示了阳性乳腺癌在接受阿贝西利和内分泌治疗时的免疫图景动态变化
Corinne H Strawser,Binita Chakraborty,Daniel Michaud et al.
Corinne H Strawser et al.
Purpose: In advanced estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therap...
Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial [0.03%]
经治寡进展性肝细胞癌患者一线系统治疗联合放疗的二期单臂多中心临床试验
Fang Shi,Haohua Wang,Yongjing Yang et al.
Fang Shi et al.
Purpose: Evidence for radiotherapy (RT) in oligoprogressive hepatocellular carcinoma (OP-HCC) is limited. We evaluated the efficacy and safety of progression-directed RT (PDRT) alongside ongoing first-line systemic therap...
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer [0.03%]
局部高危前列腺癌中免疫空间分布预测远处转移风险
David D Yang,Aya Abdelnaser,Alexander J Haas et al.
David D Yang et al.
Purpose: Computational pathology has emerged as an attractive option for improving risk stratification in prostate cancer (PCa), but most approaches either lack interpretability or focus solely on tumor morphology. We aim...
First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma [0.03%]
局部表达 interleukin-2的细胞治疗产品在复发性卵巢癌患者中的首次人体试验
Helen D Clark,Samira Aghlara-Fotovat,Jake Schladenhauffen et al.
Helen D Clark et al.
Purpose: Platinum-resistant high-grade serous ovarian carcinomas (HGSOC) are associated with poor therapeutic outcomes. While HGSOC frequently metastasizes to the intraperitoneal (IP) cavity, the success of IP cytokine th...
A non-invasive circulating tumor DNA methylation classifier to identify benign pulmonary nodules [0.03%]
一种非侵入性循环肿瘤DNA甲基化分类器，用于识别良性肺结节
Qiaomei Guo,Chaoqiang Deng,Xufeng Pan et al.
Qiaomei Guo et al.
Background: Low-dose computed tomography (LDCT) suffers from a high false-positive rate in the evaluation of pulmonary nodules. Circulating tumor DNA (ctDNA) methylation is a promising complementary biomarker, but its det...